Neurolixis presents promising safety, tolerability, and efficacy results from their Phase 2a study

This week, Neurolixis presents promising safety, tolerability, and efficacy results from their Phase 2a study in Parkinson’s patients with levodopa-induced dyskinesia (LID) at the International Congress of Parkinson’s Disease and Movement Disorders ® in Copenhagen. The multi-center study was conducted in Sweden and managed by CTC.

“This challenging, yet very exciting, study was successfully completed based on a close collaboration between us at CTC, the Neurolixis team and the participating Investigators, with Per Svenningsson as Coordinating Investigator.”

– Måns Jergil, Clinical Research Manager at CTC.